The abstract is read at the publisher; the summary is JClub's.
In a multicenter phase I study in gastroenteropancreatic well-differentiated neuroendocrine tumors, [177Lu]lutetium-dotatate plus triapine selected 200 mCi with 150 mg as RP2D and showed an objective response rate of 21.4% (28 evaluable patients).
- Why it matters: Radiation sensitizer combinations are being explored to improve peptide receptor radionuclide therapy efficacy, but early safety and activity data are needed for [177Lu]lutetium-dotatate with triapine in GEP-NET.
- What they did: Patients received 200 mCi [177Lu]lutetium-dotatate on day 1 of four 8-week cycles plus oral triapine at 100, 150, or 200 mg from day 1 to day 14; dose escalation and expansion used RP2D selection based on safety and pharmacokinetics.
- The result: Dose-limiting toxicities occurred in 9 of 31 patients, and grade ≥3 treatment-related adverse events occurred in 77%, while cytopenias were mostly transient within 2 weeks; median progression-free survival was not reached at 23.7 months follow-up.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.